Ondine appoints RBC and Singer as joint brokers

RNS Number : 0948W

Ondine Biomedical Inc.

16 August 2022

 

Ondine Biomedical Inc.

("Ondine" or the "Company")

Ondine appoints RBC and Singer as joint brokers

Ondine Biomedical Inc. (AIM: OBI), a life sciences company which is a leader in antimicrobial photodisinfection technology, announces the appointment of RBC Capital Markets and Singer Capital Markets as the Company's joint brokers, effective immediately. 

Ends

For more information, please visit: www.ondinebio.com or contact:  

Ondine Biomedical Inc.
Carolyn Cross, CEO	[phone]
Strand Hanson Limited (Nominated and Financial Adviser)
James Harris, James Dance, Richard Johnson	[phone]
RBC Capital Markets
Rupert Walford, Kathryn Deegan	[phone]
Singer Capital Markets
Aubrey Powell, Asha Chotai	[phone]
Vane Percy & Roberts (Media Contact)
Simon Vane Percy, Amanda Bernard	[phone]

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian headquartered company led by founder and CEO, Carolyn Cross. Ondine has developed a patented, photodisinfection technology platform used in treatment and prevention therapies for a broad-spectrum of pathogens - including multidrug-resistant strains. Photodisinfection is a targeted antimicrobial which uses non-thermal light to activate a photosensitive agent. In a few minutes, this light-based therapy destroys the pathogens through an oxidative burst without any impact on human tissue.

Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Products include treatment of chronic rhinosinusitis, decolonization of infections in burns and wounds, disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia and most recently, the development of topical antiviral therapy for the upper respiratory tract to reduce viral titres and transmission of respiratory viruses (e.g., SARS-CoV-2, influenza, RSV, etc.). Ondine's technology is approved in a number of jurisdictions and has been awarded the CE mark, as well as Qualified Infectious Disease Product and Fast Track status in the US by the FDA.

 

END

 

 

APPFLFVATLIELIF